Illumina embraces RocheTwelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing. more ➔
Incyte licenses Morphosys tafasitamab in...Incyte Corp. has signed a global license agreement for commercialisation of Morphosys AGs anti-CD-19 programme tafasitamab. more ➔
Novadiscovery takes off with €5 Series A...In silico clinical trials pioneer Novadiscovery SA has raised €5m in a series A financing led by Swiss Debiopharm Innovation Fund. more ➔
Alderaan Biotechnology raise €18.5m in S... Following a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi. more ➔
North Sea Therapeutics raises US$40m in Se...NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate. more ➔
Merck and 4SC collaborate in immunooncolog...4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat. more ➔
Novo Holdings invest US$12m in AMR compani...Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund. more ➔
Fighting sepsis mortality Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality. more ➔
Antabio SAS advances cystic fibrosis progr... Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients more ➔
Hydrogel fights wound infection and inflam... Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds. more ➔
